{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:36:28Z","timestamp":1771475788040,"version":"3.50.1"},"reference-count":26,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Malignant pleural mesothelioma (MPM) is a fatal neoplasm with, if untreated, poor survival of approximately nine months from diagnosis. Until recently, phase II\u2013III immunotherapy trials did not show any significant benefit. The lack of immunotherapy efficacy can be explained by the fact that mesothelioma is a tumor with an \u201cimmune desert\u201d phenotype, meaning a non-inflamed tumor characterized by low T-cell infiltration. By administration of DCs, which were ex-vivo cultured, exposed to (tumor-associated) antigens, and subsequently activated, this \u201cimmune desert\u201d phenotype might be turned into an \u201cinflamed\u201d phenotype. Three phase I\/II studies have been performed and published using activated DCs, which support this concept. We here report on the long-term survival of patients treated with DCs in three phase I\/II studies. Methods: Survival data of the phase I\/II trials using DC therapy in MPM patients were obtained and subsequently analyzed. In the first two trials, DCs were loaded with autologous tumor lysate. In the third trial, DCs were loaded with allogeneic mesothelioma tumor cell line lysate. Results: In the three studies combined, 29 patients with MPM were treated with DC vaccination between 2006 and 2015. At data cut-off, the median OS was 27 months (95% CI: 21\u201347 months). OS at 2 years was 55.2% (95% CI: 39.7\u201376.6%), and OS at 5 years was 20.7% (95% CI: 10.1\u201342.2%). Conclusions: The long-term survival of DC therapy in MPM in these three trials is promising, which is the basis for the randomized phase II\/III DENIM study. This DENIM study is currently enrolling, and the results of which have to be awaited for definite conclusions.<\/jats:p>","DOI":"10.3390\/vaccines9050525","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T21:49:21Z","timestamp":1621460961000},"page":"525","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I\/II Trials"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5578-7902","authenticated-orcid":false,"given":"Daphne W.","family":"Dumoulin","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Cornelissen","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koen","family":"Bezemer","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara J.","family":"Baart","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Erasmus MC, 3015 GD Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim G. J. V.","family":"Aerts","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III Study of Pemetrexed in Combination with Cisplatin versus Cisplatin Alone in Patients with Malignant Pleural Mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomized Phase III Study of Cisplatin with or without Raltitrexed in Patients with Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada","volume":"23","author":"Gaafar","year":"2005","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A Multicentre Randomised Phase III Trial Comparing Pembrolizumab versus Single-Agent Chemotherapy for Advanced Pre-Treated Malignant Pleural Mesothelioma: The European Thoracic Oncology Platform (ETOP 9-15) PROMISE-Meso Trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_4","unstructured":"(2021, February 25). Approves Nivolumab and Ipilimumab for Unresectable Malignant Pleural Mesothelioma, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-Line Nivolumab plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743): A Multicentre, Randomised, Open-Label, Phase 3 Trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non\u2013Small-Cell Lung Cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.1016\/j.jtho.2019.08.486","article-title":"OA14.04 Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017\/057: Nivolumab vs Docetaxel in Previously Treated NSCLC","volume":"14","author":"Gettinger","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater","volume":"37","author":"Reck","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Galluzzi, L., Chan, T.A., Kroemer, G., Wolchok, J.D., and L\u00f3pez-Soto, A. (2018). The Hallmarks of Successful Anticancer Immunotherapy. Sci. Transl. Med., 10.","DOI":"10.1126\/scitranslmed.aat7807"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","article-title":"The PD-1\/PD-L1-Checkpoint Restrains T Cell Immunity in Tumor-Draining Lymph Nodes","volume":"38","author":"Dammeijer","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.2217\/fon-2017-0234","article-title":"Is Immunotherapy a Viable Option in Treating Mesothelioma?","volume":"13","author":"Dumoulin","year":"2017","journal-title":"Future Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ceresoli, G.L., Bombardieri, E., and D\u2019Incalci, M. (2019). Immunotherapy of Mesothelioma: Vaccines and Cell Therapy. Mesothelioma: From Research to Clinical Practice, Springer International Publishing.","DOI":"10.1007\/978-3-030-16884-1"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1158\/1078-0432.CCR-17-2522","article-title":"Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human","volume":"24","author":"Aerts","year":"2018","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","article-title":"Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma","volume":"193","author":"Cornelissen","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1164\/rccm.200909-1465OC","article-title":"Consolidative Dendritic Cell-Based Immunotherapy Elicits Cytotoxicity against Malignant Mesothelioma","volume":"181","author":"Hegmans","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S295","DOI":"10.1016\/j.jtho.2016.11.304","article-title":"OA13.06 Autologous Dendritic Cells Loaded with Allogeneic Tumor Cell Lysate (Pheralys\u00ae) in Patients with Mesothelioma: Final Results of a Phase I Study","volume":"12","author":"Aerts","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Aerts, J.G., and Hegmans, J.P. (2013). Tumor-Specific Cytotoxic T Cells Are Crucial for Efficacy of Immunomodulatory Antibodies in Patients with Lung Cancer. Cancer Res.","DOI":"10.1158\/0008-5472.CAN-12-3932"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Vroman, H., Balzaretti, G., Belderbos, R.A., Klarenbeek, P.L., van Nimwegen, M., Bezemer, K., Cornelissen, R., Niewold, I.T.G., van Schaik, B.D., and van Kampen, A.H. (2020). T Cell Receptor Repertoire Characteristics Both before and Following Immunotherapy Correlate with Clinical Response in Mesothelioma. J. Immunother. Cancer, 8.","DOI":"10.1136\/jitc-2019-000251"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"815","DOI":"10.21873\/anticanres.13180","article-title":"Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-Small Cell Lung Cancer","volume":"39","author":"Katsurada","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Chardin, D., Paquet, M., Schiappa, R., Darcourt, J., Bailleux, C., Poudenx, M., Sciazza, A., Ilie, M., Benzaquen, J., and Martin, N. (2020). Baseline Metabolic Tumor Volume as a Strong Predictive and Prognostic Biomarker in Patients with Non-Small Cell Lung Cancer Treated with PD1 Inhibitors: A Prospective Study. J. Immunother. Cancer, 8.","DOI":"10.1136\/jitc-2020-000645"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1158\/1078-0432.CCR-17-2386","article-title":"Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab","volume":"24","author":"Joseph","year":"2018","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"798467","DOI":"10.1155\/2010\/798467","article-title":"Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity","volume":"2010","author":"Veltman","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e1474318","DOI":"10.1080\/2162402X.2018.1474318","article-title":"Low-Dose Cyclophosphamide Depletes Circulating Na\u00efve and Activated Regulatory T Cells in Malignant Pleural Mesothelioma Patients Synergistically Treated with Dendritic Cell-Based Immunotherapy","volume":"7","author":"Noordam","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of Tumour Mutational Burden with Outcomes in Patients with Advanced Solid Tumours Treated with Pembrolizumab: Prospective Biomarker Analysis of the Multicohort, Open-Label, Phase 2 KEYNOTE-158 Study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"de Gooijer, C.J., van der Noort, V., Stigt, J.A., Baas, P., Biesma, B., Cornelissen, R., van Walree, N., van Heemst, R.C., Soud, M.Y.-E., and Groen, H.J.M. (2021). Switch-Maintenance Gemcitabine after First-Line Chemotherapy in Patients with Malignant Mesothelioma (NVALT19): An Investigator-Initiated, Randomised, Open-Label, Phase 2 Trial. Lancet Respir. Med.","DOI":"10.2139\/ssrn.3520057"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"280","DOI":"10.21037\/tlcr.2019.05.05","article-title":"A Multicenter, Randomized, Phase II\/III Study of Dendritic Cells Loaded with Allogeneic Tumor Cell Lysate (MesoPher) in Subjects with Mesothelioma as Maintenance Therapy after Chemotherapy: DENdritic Cell Immunotherapy for Mesothelioma (DENIM) Trial","volume":"8","author":"Belderbos","year":"2019","journal-title":"Transl. Lung Cancer Res."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/5\/525\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:03:45Z","timestamp":1760162625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/5\/525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["vaccines9050525"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9050525","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,19]]}}}